Topical immunotherapy in dermatology

International Journal of Clinical Practice

Volumn 53, Issue 2, 1999, Pages 130-137

  Buckley, D A ^a   Du Vivier, A W P ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; DIPHENCYPRONE; SQUARIC ACID DIBUTYL ESTER;

ALOPECIA AREATA; BLISTER; CLINICAL TRIAL; DRUG MECHANISM; ECZEMA; ERYTHEMA MULTIFORME; HUMAN; IMMUNOTHERAPY; INFORMED CONSENT; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN SENSITIZATION; TOPICAL DRUG ADMINISTRATION; VERRUCA VULGARIS; VITILIGO; WART VIRUS;

ADMINISTRATION, TOPICAL; ALLERGENS; ALOPECIA AREATA; CYCLOBUTANES; CYCLOPROPANES; DECISION MAKING; DINITROCHLOROBENZENE; HUMANS; IMMUNOTHERAPY; WARTS;

EID: 0033000157     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Bystryn JC, Tamesis J. Immunologic aspects of hair loss. J Invest Dermatol 1991; 96: 88S-89S.
2. Majewski S, Jablonska S. Immunology of HPV infection and HPV-associated tumours. Int J Dermatol 1998; 37: 81-95.
3. DeBerker D, Ibbotson S, Simpson NB et al. Reduced experimental contact sensitivity in squamous cell but not basal cell carcinomas of skin. Lancet 1995; 345: 425-426.
4. Mitchell AJ, Krull EA. Alopecia areata: pathogenesis and treatment. J Am Acad Dermatol 1984; 11: 763-775.
5. Rhodes EL, Dolman W, Kennedy C, Taylor RR. Alopecia areata regrowth induced by Primula obconica. Br J Dermatol 1981; 104: 339-340.
6. Lewis HM. Topical immunotherapy of refractory warts. Cutis 1973; 12: 863-867.
7. Breslow BM, Haynie R, Mirra J. Synthesis of diphenylcyclopropenone. J Am Chem Soc 1959; 81: 247-248.
8. Wilkerson MG, Henkin J, Wilkin JK. Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitisation and photochemical stability. J Am Acad Dermatol 1984; 11: 802-807.
9. Van der Steen PHM, Van Baar HMJ, Perret CM, Happle R. Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991; 24: 253-257.
10. Hausen BM, Stute J. Diphenylcyclopropenone: a strong contact sensitiser. Chem and Industry 1980; 17: 699-700.
11. Stute J, Hausen BM, Schulz KH. Diphenylcyclopropenon: ein stark wirksames Kontaktallergen. Dermatosen 1981; 29: 12-15.
12. Friedli A, Hunziker T, Finkel B, Braathen LR. Effects of acute, low-dose UVB radiation on the induction of contact hypersensitivity to diphenylcyclopropenone in man. Arch Dermatol Res 1993; 285: 1-5.
13. Van der Steen PHM, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin 1993; 11: 619-622.
14. Mayerhausen W, Remy W. Testung der zellularen Immunreaktivitat bei Melanompatienten mit Diphenylcyclopropenon (DPCP) im Vergleich mit Dinitrochlorobenzol (DNCB). Hautarzt 1987; 38: 449-452.
15. Whittaker M. Severe dermatitis caused by diphencyprone. Contact Dermatitis Newsletter 1972; 11: 264.
16. Ammon HL. Structures of and charge separation in 2,3-diphenyl-4,4-ducyanotriafulvene and 2,3-diphenylcyclopropenone. J Am Chem Soc 1973; 95: 7093-7094.
17. Sansom JE, Molloy KC, Lovell CR. Occupational sensitisation to diphencyprone in a chemist. Contact Dermatitis 1995; 32: 363.
18. Shah M, Lewis FM, Messenger AG. Hazards in the use of diphencyprone. Br J Dermatol 1996; 134: 1153.
19. Adisesh A, Beck M, Cherry NM. Hazards in the use of diphencyprone. Br J Dermatol 1997; 136: 470.
20. Wilkerson MG, Connor TH, Henkin J et al. Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. J Am Acad Dermatol 1987; 17: 606-611.
21. Berth-Jones J, McBurney A, Hutchinson PE. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venereol (Stockh) 1994; 74: 312-313.
22. Happle R, Echternacht K. Induction of hair growth in alopecia areata with DNCB. Lancet 1977; 2: 1002-1003.
23. Romaguera Sagrera C, Castel T, Pedragosa R, Pinol Aguade J. Tratamiento de epiteliomas con DNCB. Med Cutan Iber Lat Amer 1974; 6: 471-476.
24. Holmes EC, Eilber FR, Morton DL. Immunotherapy of malignancy in humans. JAMA 1975; 232: 1052-1055.
25. Malek-Mansour S, Castermans-Elias S, Lapiere CM. Regression de metastases de melanome après therapeutique immunologique. Dermatologica 1973; 146: 156-162.
26. Stricker RB, Goldberg B, Epstein WL. Immunological changes in patient with systemic lupus erythematosus treated with topical dinitrochlorobenzene. Lancet 1995; 345: 1505-1506.
27. Stricker RB, Elswood BF, Goldberg B et al. Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene. J Am Acad Dermatol 1994; 31: 462-466.
28. Shapiro J. Topical immunotherapy in the treament of chronic severe alopecia areata. Dermatol Clin 1993; 11: 611-617.
29. Naylor MF, Neldner KH, Yarbrough GK et al. Contact immunotherapy of resistant warts. J Am Acad Dermatol 1988; 19: 679-683.
30. Kratka J, Goerz G, Vizethum W, Strobel R. Dinitrochlorobenzene: influence on the cytochrome P-450 system and mutagenic effects. Arch Dermatol Res 1979; 266: 315-318.
31. DeLeve LD. Dinitrochlorobenzene is genotoxic by sister chromatid exchange in human skin fibroblasts. Mutation Res 1996; 371: 105-108.
32. Wilkerson M, Wilkin J, Smith R. Contaminants of dinitrochlorobenzene. J Am Acad Dermatol 1983; 9: 554-557.
33. Happle R, Buchner U, Kalveram KJ, Echternacht-Happle K. Contact allergy as a therapeutic tool for alopecia areata: comparison between dinitrochlorobenzene and squaric acid dibutyl ester. Arch Dermatol Res 1979; 264: 101-102.
34. Happle R, Kalveram KJ, Buchner U et al. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutyl ester. Dermatologica 1980; 161: 289-297.
35. Claudy AL, Roche H. Traitement des verrues multiples et recidivantes par induction d'une hypersensibilite retardee: etude critique de l'utilisation du dibutylester de l'acide squarique. Ann Dermatol Venereol 1981; 108: 765-767.
36. Wilkerson MG, Henkin J, Wilkin JK, Smith RG. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 1985; 13: 229-234.
37. Strobel R, Rohrborn G. Mutagenic and cell transforming activities of 1-chloro-2,4-dinitrochlorobenzene (DNCB) and squaric acid dibutyl ester (SADBE). Arch Toxicol 1980; 45: 307-314.
38. Rosenberg E, Drake L. In: discussion of Dunaway D: Alopecia areata. Arch Dermatol 1976; 112: 256.
39. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 1983; 63: 49-52.
40. Iijima S, Otsuka F. Prognostic factors for clinical response of alopecia areata to topical immunotherapy with squaric acid dibutyl ester. Arch Dermatol 1997; 133: 539-540.
41. Weise K, Kretschmar L, John SM, Hamm H. Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 1996; 192: 129-133.
42. Van der Steen PHM, Van Baar HMJ, Happle R et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991; 24: 227-230.
43. DeProst Y, Paquez F, Touraine R. Dinitrachlorobenzene treatment of alopecia areata. Arch Dermatol 1982; 118: 542-545.
44. Brouillard F, Szapiro E. Dinitrochlorobenzene in alopecia areata. Lancet 1978; ii: 1304.
45. Friedmann PS. Dinitrochlorobenzene and alopecia. Lancet 1979; i: 1412.
46. Friedmann PS. Response of alopecia areata to DNCB: influence of autoantibodies and route of sensitisation. Br J Dermatol 1981; 185: 285-289.
47. Tackling warts on the hands and feet. Drug Ther Bull 1998; 36: 22-24.
48. Wiesner-Menzel L, Happle R. Ruckbildung von Plantarwarzen nach Behandlung mit Diphencyprone. Z Hautkr 1984; 59: 1080-1083.
49. Buckley DA, Keane FM, Munn SE et al. Immunotherapy of recalcitrant warts with diphencyprone. Br J Dermatol 1998; 139(suppl 51): 24.
50. Lane PR, Hogan DJ. Diphencyprone (letter). J Am Acad Dermatol 1988; 19: 364-365.
51. Orecchia G, Douville H, Santagostino I, Rabbiosi G. Treatment of multiple relapsing warts with diphenciprone. Dermatologica 1988; 177: 225-231.
52. Rampen FHJ, Steijlen PM. Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Dermatology 1996; 193: 236-238.
53. Van der Steen P, Van de Kerkhof P, Der Kinderen D et al. Clinical and immunohistochemical responses of plantar warts to topical immunotherapy with diphenylcyclopropenone. J Dermatol 1991; 18: 330-333.
54. Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet 1989; ii: 445.
55. Williams AC, Klein E. Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer 1970; 25: 450-462.
56. Macdonald Hull S, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 1991; 125: 164-168.
57. Schuttelaar M-La, Hamstra JJ, Plinck EPB et al. Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 1996; 135: 581-585.
58. Orecchia G, Malagola P. Topical immunotherapy in children with alopecia areata. J Invest Dermatol 1995; 104: 35S-36S.
59. Hoffman R, Happle R. Topical immunotherapy in alopecia areata: what, how and why? Dermatol Clin 1996; 14: 739-744.
60. Gordon PM, Aldridge RD, McVittie E, Hunter JAA. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months follow-up. Br J Dermatol 1996; 134: 869-871.
61. Orecchia G, Rabbiosi G. Treatment of alopecia areata with diphencyprone. Dermatologica 1985; 171: 193-196.
62. Monk B, Williams HC. Topical diphencyprone therapy in alopecia areata. Br J Dermatol 1988; 119(suppl 33): 16-17.
63. Kietzman H, Hardung H. Treatment of alopecia areata with diphenylcyclopropenone. Acta Derm Venereal (Stockh) 1985; 65: 274-275.
64. Ashworth J, Tuyp E, Mackie RM. Allergic and irritant contact dermatitis compared in the treatment of alopecia totalis and universalis: a comparison of the value of topical diphencyprone and tretinoin gel. Br J Dermatol 1989; 120: 397-401.
65. Berth-Jones J, Hutchinson P. Treatment of alopecia totalis with a combination of inosine prabonex and diphencyprone compared to each treatment alone. Clin Exp Dermatol 1991; 16: 172-175.
66. Hoting E, Boehm A. Therapy of alopecia with diphencyprone. Br J Dermatol 1992; 127: 625-629.
67. Tosti A, Guerra L, Capobianco B, Brasile GP. Terapia sensibilizzante nell'alopecia areata grave. G Ital Dermatol Venereol 1988; 123: 571-573.
68. Hatzis J, Georgiotouo K, Kostakis P et al. Treatment of alopecia areata with diphencyprone. Austral J Dermatol 1989; 29: 33-36.
69. MacDonald Hull S, Norris J. Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol 1988; 119: 367-374.
70. MacDonald Hull S, Cunliffe W. Successful treatment of alopecia areata using the contact allergen diphencyprone. Br J Dermatol 1991; 124: 212-213.
71. Shapiro J, Tan J, Ho V et al. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1993; 29: 729-735.
72. Ochsendorf FR, Mitrou G, Milbradt R. Treatment of alopecia areata with diphenylcyclopropenone. Z Hautkr 1988; 63: 94-100.
73. Monk B. Induction of hair growth in alopecia totalis with diphencyprone sensitisation. Clin Exp Dermatol 1989; 14: 154-157.
74. Tosti A, Caponeri GM, Primativo R et al. Dibutilestere dell'acido squarico e difenciprone nella terapia dell'alopecia areata. G Ital Dermatol Venereol 1985: 120: 371-373.
75. Ro BI. Alopecia areata in Korea. J Dermatol 1995; 22: 858-864.
76. Kietzmann H, Hardung H, Christophers E. Therapie der alopecia areata mit diphenylcyclopropenon. Hautarzt 1985; 36: 331-335.
77. Flowers FP, Slazinski L, Fenske NA, Pullara TJ. Topical squaric acid dibutyl ester therapy for alopecia areata Cutis 1982; 30: 733-736.
78. Gianetti A, Orecchia G. Clinical experience on the treatment of alopecia areata with squaric acid dibutyl ester. Dermatologica 1983; 167: 280-282.
79. Case PC, Mitchell AJ, Swanson NA et al. Topical therapy of alopecia areata with squaric acid dibutyl ester. J Am Acad Dermatol 1984; 10: 447-451.
80. Barth JH, Darley CR, Gibson JR. Squaric acid dibutyl ester in the treatment of alopecia areata. Dermatologica 1985; 170: 40-42.
81. Caserio RJ. Treatment of alopecia areata with squaric acid dibutyl ester. Arch Dermatol 1987; 123: 1036-1041.
82. Micali G, Cicero RL, Nasca MR, Sapuppo A. Treatment of alopecia areata with squaric acid dibutyl ester. Int J Dermatol 1996; 35: 52-56.
83. Daman LA, Rosenberg EW, Drake L. Treatment of alopecia areata with dinitrochlorobenzene. Arch Dermatol 1978; 114: 1036-1038.
84. Happle R, Cebulla K, Echternacht-Happle K. Dinitrochlorobenzene therapy for alopecia areata. Arch Dermatol 1978; 114: 1629-1631.
85. Hehir M, Du Vivier A. Alopecia areata treated with DNCB. Clin Exp Dermatol 1979; 4: 385-386.
86. Van der Steen PHM, Boezeman JBM, Happle R. Topical immunotherapy for alopecia areata: reevaluation of 139 cases after an additional follow-up period of 19 months. Dermatology 1992; 184: 198-201.
87. MacDonald Hull S, Cunliffe W. Post therapy relapse rate in alopecia areata after successful treatment with diphencyprone. J Dermatol Treat 1989; 1: 71-74.
88. MacDonald Hull S, Cunliffe W. Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1992; 26: 276-277.
89. Naldi L, Parazzini F, Cainelli T and the reading group. Role of topical immunotherapy in the treatment of alopecia areata. J Am Acad Dermatol 1990; 22: 654-656.
90. Orecchia G, Marelli MA, Perfetti L, Rabbiosi G. Alopecia areata: more on topical sensitisers. Dermatologica 1990; 180: 57-59.
91. Tosti A, Guidetti MS, Bardazzi F, Misciali C. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996; 35: 199-201.
92. Vestey JP, Savin JA. Natural history of severe alopecia areata. Br J Dermatol 1987; 117: 531.
93. Tosti A, DePadova MP, Minghetti G, Veronesi S. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol 1986; 15: 209-210.
94. Dunagin WG, Millikan LE. Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalities. J Am Acad Dermatol 1982; 6: 40-45.
95. Bekhor PS, Entwisle BR, McKenzie IFC. Topical DNCB therapy for resistant warts. Australas J Dermatol 1978; 19: 28-30.
96. Eriksen K. Treatment of the common wart by induced allergic inflammation. Dermatologica 1980; 160: 161-166.
97. Goihman-Yahr M, Fernandez J, Convit J. Immunoterapia de las verrugas vulgares diseminadas con dinitroclorobenceno. Med Cutan Iber Lat Amer 1976; 4: 187-193.
98. Nater JP, Barr AJM, Bleumink E. De behandleling van verrucae vulgares met 2,4-dinitrochloorbenzeen (DNCB). Ned Tijdschr Geneeskd 1979; 123: 603-606.
99. Buckner D, Price N. Immunotherapy of verrucae vulgares with dinitrochlorobenzene. Br J Dermatol 1978; 98: 451-455.
100. Claudy AL, Roche H, Gogue Y. Traitement des verrues multiples et recidivantes par induction d'une hypersensibilite retardee. Ann Dermatol Venereol 1980; 107: 551-553.
101. Johansson E, Forstrom L. Dinitrochlorobenzene (DNCB) treatment of viral warts. Acta Derm Venereol (Stockh) 1984; 64: 529-533.
102. Iijima S, Otsuka F. Contact immunotherapy with squaric acid dibutyl ester for warts. Dermatology 1993; 187: 115-118.
103. Massing AM, Epstein WL. Natural history of warts: a two-year study. Arch Dermatol 1963; 87: 306-310.
104. Swanson NA, Mitchell AJ, Leahy MS et al. Topical treatment of alopecia areata: contact allergen versus primary irritant therapy. Arch Dermatol 1981; 117: 384-387.
105. McDonald Hull S, Cunliffe WJ, Norris JF. Alopecia areata treated with diphencyprone: is an allergic response necessary? Br J Dermatol 1990; 122: 716-717.
106. Baadsgaard O, Lindskov R, Clemmensen OJ. In situ lymphocyte subsets in alopecia areata before and during treatment with a contact allergen. Clin Exp Dermatol 1987; 12: 260-264.
107. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Rev 1980; 267: 109-114.
108. Happle R, Klein HM, Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986; 278: 214-218.
109. Brocker EB, John SM, Steinhausen D, Hamm H. Topical immunotherapy with contact allergens in alopecia areata: evidence for non-specific systemic suppression of cellular immune reactions. Arch Dermatol Res 1991; 283: 133-134.
110. Goldsmith L. Summary of alopecia areata research workshop and future research directions. J Invest Dermatol 1991; 96: 98S-100S.
111. Hoffman R, Wenzel E, Huth A et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994; 103: 530-533.
112. Hoffman R, Wenzel E, Huth A et al. Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphencyprone. Acta Derm Venereol (Stockh) 1996; 76: 17-20.
113. Brocker E-B, Echternacht-Happle K, Hamm H, Happle R. Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol 1987; 88: 564-568.
114. Henderson CA, Ilchyshyn A. Vitiligo complicating diphencyprone sensitisation therapy for alopecia universalis. Br J Dermatol 1995; 133: 496-497.
115. Duhra P, Foulds IS. Persistant vitiligo induced by diphencyprone. Br J Dermatol 1990; 123: 415-416.
116. MacDonald-Hull SP, Cotterill JAC, Norris JFB. Vitiligo following diphencyprone dermatitis. Br J Dermatol 1989; 120: 323.
117. Hatzis J, Gourgiotou K, Tosca A et al. Vitiligo as a reaction to topical treatment with diphencyprone. Dermatologica 1988; 177: 146-148.
118. Valsecchi R, Cainelli T. Depigmentation from squaric acid dibutyl ester. Contact Dermatitis 1984; 10: 109.
119. Valsecchi R, Pansera B, Rossi A, Cainelli T. Anomalie pigmentaire in corso di immunoterapia topica per l'alopecia areata. G Ital Dermatol Venereol 1989; 124: 31-32.
120. Van der Steen P, Happle R. 'Dyschromia in confetti' as a side-effect of topical immunotherapy with diphenylcyclopropenone. Arch Dermatol 1992; 128: 518-520.
121. Tosti A, Guerra L, Bardazzi F. Contact urticaria during topical immunotherapy. Contact Dermatitis 1989; 21: 196-197.
122. Valsecchi R, Foiadelli L, Reseghetti A, Cainelli T. Generalised urticaria from DNCB. Contact Dermatitis 1986; 14: 254-255.
123. Van Hecke E, Santosa S. Contact urticaria to DNCB. Contact Dermatitis 1985; 12: 282.
124. McDaniel DH, Blatchley DM, Welton WA. Adverse systemic reaction to dinitrochlorobenzene. Arch Dermatol 1982: 118: 371.
125. Perret CM, Steijlen PM, Zaun H, Happle R. Erythema multiforme-like eruptions: a rare side-effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica 1990; 180: 5-7.
126. Kim JK, Lee HS, Yoon TJ et al. Erythema multiforme due to diphenylcyclopropenone. Ann Dermatol 1996; 8: 250-252.
127. Oh C-W, Han K-D, Kim T-H. Bullous erythema multiforme following topical diphenylcyclopropenone application. Contact Dermatitis 1998; 38: 220-221.
128. Viraben R, Lahrousse JL, Bazex J. Erythema multiforme due to DNCB. Contact Dermatitis 1990; 22: 179-191.
129. Frattasio A, Germino M, Cargnello S, Patrone P. Side-effects during treatment with SADBE. Contact Dermatitis 1997; 36: 118-119.
130. Barth JH, Darley CR, Gibson JR. Squaric acid esters in the treatment of alopecia areata. J Am Acad Dermatol 1986; 14: 846.
131. Fowler JF, Hodge SJ, Tobin GR. Persistent allergic contact dermatitis from squaric acid dibutyl ester. J Am Acad Dermatol 1993; 28: 259-260.
132. Nasca MR, Cicero RL, Innocenzi D, Micali G. Persistent allergic contact dermatitis at the site of primary sensitisation with squaric acid dibutyl ester. Contact Dermatitis 1995; 33: 438.
133. Nishioka K. Ogasawara M, Kurata K, Asagami C. Iatrogenic benign lymphoplasia induced by allergic contact dermatitis from squaric acid dibutyl ester: immunohistologic study of cellular infiltrates. Contact Dermatitis 1993; 28: 3-5.
134. Puig L, Alegre M, Cuatrecasas M, Moragas JM. Erythema multiforme-like reaction following diphencyprone treatment of plane warts. Int J Dermatol 1994; 33: 201-203.
135. Orecchia G, Perfetti L. Vitiligo and topical allergens. Dermatologica 1989; 179: 137-138.